Navigation Links
NIH funds development of new broad-spectrum therapeutics
Date:10/13/2011

Four companies are to develop broad-spectrum therapeuticsantibiotics, antivirals and an antitoxinto prevent or treat diseases caused by multiple types of bacteria or viruses, under contracts awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. Total funding for the four contracts could reach $150 million over a maximum five-year period.

The contracts are designed to support essential research and development activities to enable promising investigational therapies to move toward early-phase clinical studies and, if successful in clinical studies, on to eventual licensure. The ultimate goal is to develop products that the U.S. government can stockpile to protect the public in the event of a bioterror attack or public health crisis.

In line with NIAID's strategic plan for biodefense and emerging infectious diseases research, these contracts move beyond the paradigm of drug development that is sometimes called "one-bug, one-drug." (http://www.niaid.nih.gov/topics/BiodefenseRelated/Biodefense/Documents/biosp2007.pdf)The contracts are to focus on candidate therapies that can be used against classes of pathogens rather than being agent-specific. Such broad-spectrum therapeutics would improve preparedness for all infectious threats, whether they occur naturally or are deliberately introduced.

The following companies are recipients of the new contracts:

CUBRC Inc., Buffalo, N.Y., in partnership with Tetraphase Pharmaceuticals, Watertown, Mass.Researchers will develop a fully synthetic tetracycline product, TP-271, to treat the bacterial disease tularemia, and respiratory infections such as community-acquired bacterial pneumonia. Both intravenous and oral formulations of the drug will be evaluated in preclinical studies for safety and efficacy, and several preliminary 1 clinical trials are planned. The compound will also be tested in nonclinical studies for activity against anthrax and plague. The initial award is for $5.7 million, with the potential for up to $35 million over five years.

Enanta Pharmaceuticals Inc., Watertown, Mass.Researchers will develop and evaluate a candidate from a novel class of next-generation broad-spectrum antibiotics known as bicyclolides. Bicyclolides are small-molecule anti-infectives. Enanta's bicyclolide has demonstrated potential for activity against anthrax, plague and tularemia in cell culture studies, as well as efficacy against anthrax and tularemia in mice. The compound will be evaluated for effectiveness against multiple bacteria that might be used as agents of bioterror, and several Phase 1 clinical trials are planned. Bicyclolides represent a promising new class of broad-spectrum antibiotics that have demonstrated activity against the two major groups of bacteria, known as gram-negative and gram-positive bacteria. These groups of bacteria are distinguished by the presence or absence of peptidoglycan, which is visible in lab specimens when the bacteria are stained using the Gram method. In general, the two types of bacteria are treated using different types of drugs.The initial award is for $14.3 million with the potential for a five-year total of up to $43 million.

Unither Virology LLC, Silver Spring, Md.Unither will develop and evaluate UV-4, an investigational antiviral drug with potential as a treatment for influenza and dengue fever and possible applications for viral hemorrhagic fever, smallpox and hepatitis. The drug is derived from a class of compounds known as iminosugars that includes drugs approved for other indications, such as diabetes and Gaucher's disease. UV-4, which may also reduce the potential for drug resistance, is expected to undergo toxicity studies, a preliminary safety study and a Phase 2 clinical trial for dengue fever. Unither has received an initial award of $10.5 million with the potential for up to $45 million over five years.

XOMA (US) LLC, Berkeley, Calif.The company will develop an intravenous antitoxin to treat human botulism poisoning. XOMA's monoclonal antibody product will target serotypes C and D of Clostridium botulinum neurotoxin and would also neutralize C/D and D/c mosaic/hybrid toxins. The development of human botulinum monoclonal antibodies would replace existing horse-based antitoxin products that are difficult to make and pose safety concerns for humans. A preliminary clinical trial is planned for XOMA's anti-C/D toxin product. The company received $7 million in its initial NIAID award with the potential for up to $28 million in five years.


'/>"/>

Contact: Ann Mosher
niaidnews@niaid.nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
Source:Eurekalert

Related medicine news :

1. Federal Recovery Funds Allow Eries Shriners Hospital to Reduce Energy Costs, Invest Savings in Patient Care
2. Three Security Firms Create Consortium To Automate Meaningful Use Requirements And Qualify Clients For $Billions In Stimulus Funds
3. Study: Federal funds support health depts., but leadership is key
4. Legacy(SM) Case for Tobacco Funds to be Heard by Ohio Supreme Court
5. Miles for Hope’s Moving Towards A Cure(SM) Brain Tumor Walk in Boston Raising Funds for Brain Tumor Vaccine and Massachusetts General Hospital
6. EVMS receives more than $1 million in federal funds to develop new ways to reverse type 1 diabetes
7. Major League Baseball Players Alumni Help Lazarex Cancer Foundation Raise Funds
8. Prize4Life Launches “Art, Life, Spring” Online Art Auction to Raise Funds for Lou Gehrig's Disease Research
9. Just Graduated College Seniors Ride for Loved Ones With Diabetes Cycling Cross Country to Raise Funds to Help Find a Cure
10. Only 5 percent of cancer research funds are spent on metastases, yet it kills 90 percent of all cancer patients
11. Amazing Grace Charity Golf Tournament to Raise Awareness, Funds for Neuroblastoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... Cary, North Carolina (PRWEB) , ... June 26, 2016 , ... ... the release of a new product that was developed to enhance the health of ... harvested for centuries. , The two main herbs in the PawPaws Cat Kidney ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, can ... Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey ... cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under ...
(Date:6/25/2016)... ... , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his Bachelors ... Geffen School of Medicine at UCLA. He trained in Internal Medicine at Scripps Green ... hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to train ...
(Date:6/24/2016)... Los Angeles, CA (PRWEB) , ... June 24, 2016 , ... ... plastic surgery procedures that most people are unfamiliar with. The article goes on to ... known procedures, but also many of these less common operations such as calf and ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association ... it will receive two significant new grants to support its work to advance ... 25th anniversary by recognizing patients, medical professionals and scientists for their work in ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Market - Forecast to 2022" report to their offering. ... method for the patients with kidney failure, it replaces the ... from the patient,s blood and thus the treatment helps to ... chloride in balance. Increasing number of ESRD ...
(Date:6/23/2016)... 2016 Roche (SIX: RO, ROG; OTCQX: RHHBY) ... Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated testing ... With this clearance, Roche is the first IVD company ... for sepsis risk assessment and management. PCT ... PCT levels in blood can aid clinicians in assessing ...
(Date:6/23/2016)... , June 23, 2016 Bracket , ... launch its next generation clinical outcomes platform, Bracket eCOA (SM) ... held on June 26 – 30, 2016 in ... first electronic Clinical Outcome Assessment product of its kind to ... #715. Bracket eCOA 6.0 is a flexible platform ...
Breaking Medicine Technology: